|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACSF2 |
Gene summary for ACSF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACSF2 | Gene ID | 80221 |
| Gene name | acyl-CoA synthetase family member 2 | |
| Gene Alias | ACSMW | |
| Cytomap | 17q21.33 | |
| Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | Q96CM8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80221 | ACSF2 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.21e-09 | 4.46e-01 | -0.1954 |
| 80221 | ACSF2 | A015-C-203 | Human | Colorectum | FAP | 1.27e-07 | 7.70e-02 | -0.1294 |
| 80221 | ACSF2 | A001-C-108 | Human | Colorectum | FAP | 8.51e-04 | -1.98e-01 | -0.0272 |
| 80221 | ACSF2 | A002-C-205 | Human | Colorectum | FAP | 1.19e-07 | -2.94e-01 | -0.1236 |
| 80221 | ACSF2 | A015-C-006 | Human | Colorectum | FAP | 5.24e-04 | -2.66e-01 | -0.0994 |
| 80221 | ACSF2 | A002-C-114 | Human | Colorectum | FAP | 1.19e-04 | -1.76e-01 | -0.1561 |
| 80221 | ACSF2 | A015-C-104 | Human | Colorectum | FAP | 1.11e-07 | -8.63e-02 | -0.1899 |
| 80221 | ACSF2 | A001-C-014 | Human | Colorectum | FAP | 8.59e-04 | -2.11e-01 | 0.0135 |
| 80221 | ACSF2 | A002-C-016 | Human | Colorectum | FAP | 1.24e-06 | -2.37e-01 | 0.0521 |
| 80221 | ACSF2 | A015-C-002 | Human | Colorectum | FAP | 2.48e-02 | -2.41e-01 | -0.0763 |
| 80221 | ACSF2 | A001-C-203 | Human | Colorectum | FAP | 1.24e-02 | -7.30e-02 | -0.0481 |
| 80221 | ACSF2 | A002-C-116 | Human | Colorectum | FAP | 3.19e-10 | -2.31e-01 | -0.0452 |
| 80221 | ACSF2 | A014-C-008 | Human | Colorectum | FAP | 1.01e-02 | -1.96e-01 | -0.191 |
| 80221 | ACSF2 | A018-E-020 | Human | Colorectum | FAP | 3.11e-04 | -1.60e-01 | -0.2034 |
| 80221 | ACSF2 | F034 | Human | Colorectum | FAP | 2.08e-05 | -1.54e-01 | -0.0665 |
| 80221 | ACSF2 | F072B | Human | Colorectum | FAP | 1.78e-02 | -1.81e-01 | 0.257 |
| 80221 | ACSF2 | HCC1_Meng | Human | Liver | HCC | 3.28e-17 | 3.96e-03 | 0.0246 |
| 80221 | ACSF2 | HCC2_Meng | Human | Liver | HCC | 1.42e-04 | 1.38e-03 | 0.0107 |
| 80221 | ACSF2 | HCC1 | Human | Liver | HCC | 5.13e-03 | 2.21e+00 | 0.5336 |
| 80221 | ACSF2 | HCC2 | Human | Liver | HCC | 2.53e-03 | 1.33e+00 | 0.5341 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
| GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0033865 | Colorectum | AD | nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:0033875 | Colorectum | AD | ribonucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:0034032 | Colorectum | AD | purine nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:00091504 | Colorectum | FAP | purine ribonucleotide metabolic process | 96/2622 | 368/18723 | 4.91e-10 | 1.20e-07 | 96 |
| GO:00061634 | Colorectum | FAP | purine nucleotide metabolic process | 100/2622 | 396/18723 | 1.45e-09 | 2.77e-07 | 100 |
| GO:00092593 | Colorectum | FAP | ribonucleotide metabolic process | 97/2622 | 385/18723 | 2.90e-09 | 5.07e-07 | 97 |
| GO:00725214 | Colorectum | FAP | purine-containing compound metabolic process | 101/2622 | 416/18723 | 1.11e-08 | 1.33e-06 | 101 |
| GO:00196933 | Colorectum | FAP | ribose phosphate metabolic process | 97/2622 | 396/18723 | 1.35e-08 | 1.51e-06 | 97 |
| GO:00091174 | Colorectum | FAP | nucleotide metabolic process | 105/2622 | 489/18723 | 3.52e-06 | 1.25e-04 | 105 |
| GO:00067534 | Colorectum | FAP | nucleoside phosphate metabolic process | 105/2622 | 497/18723 | 7.47e-06 | 2.25e-04 | 105 |
| GO:00066313 | Colorectum | FAP | fatty acid metabolic process | 81/2622 | 390/18723 | 1.43e-04 | 2.24e-03 | 81 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACSF2 | SNV | Missense_Mutation | rs770288175 | c.1744N>T | p.Arg582Trp | p.R582W | Q96CM8 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ACSF2 | SNV | Missense_Mutation | c.1700G>C | p.Gly567Ala | p.G567A | Q96CM8 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ACSF2 | insertion | Frame_Shift_Ins | novel | c.1798_1799insAA | p.Gly600GlufsTer40 | p.G600Efs*40 | Q96CM8 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| ACSF2 | insertion | In_Frame_Ins | novel | c.1799_1800insATGTCTGGAGACATTTGAGCTGAGACCTGGAAA | p.Gly600_Lys601insCysLeuGluThrPheGluLeuArgProGlyLys | p.G600_K601insCLETFELRPGK | Q96CM8 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| ACSF2 | insertion | Frame_Shift_Ins | novel | c.1053_1054insTCAGGCAGGGGTGGGGGGCTGGCTGGGCTCCCCTTGCCAGCTAGAGA | p.Ala352SerfsTer54 | p.A352Sfs*54 | Q96CM8 | protein_coding | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD | ||
| ACSF2 | SNV | Missense_Mutation | novel | c.1087N>A | p.Gly363Ser | p.G363S | Q96CM8 | protein_coding | tolerated(0.15) | benign(0.241) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACSF2 | SNV | Missense_Mutation | c.553G>A | p.Ala185Thr | p.A185T | Q96CM8 | protein_coding | tolerated(0.63) | benign(0.06) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ACSF2 | SNV | Missense_Mutation | rs780707588 | c.640N>A | p.Val214Ile | p.V214I | Q96CM8 | protein_coding | tolerated(0.55) | benign(0) | TCGA-MA-AA3W-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACSF2 | SNV | Missense_Mutation | novel | c.1083C>A | p.Phe361Leu | p.F361L | Q96CM8 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| ACSF2 | SNV | Missense_Mutation | novel | c.1073N>G | p.Ser358Cys | p.S358C | Q96CM8 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |